造血细胞移植后结局:ST2为何成为「金块」生物标志物
该综述指出,异基因造血细胞移植(HCT)是最经临床验证的肿瘤免疫治疗,但受移植物抗宿主病(GVHD)等毒性限制。借助基因组学、转录组学、蛋白质组学和细胞组学进展,HCT后血液生物标志物已在诊断、预后分层和预测GVHD治疗反应及非复发死亡方面获得验证。文章以可溶性STimulation-2(sST2,IL-33诱饵受体)为例,梳理从标志物发现到首次临床相关的路径。
要点
- sST2是HCT后最经充分验证的血液生物标志物。
- 血液标志物可用于GVHD诊断、预后分层及预测治疗反应。
- 标志物有助于实现及时且选择性的治疗干预。
核心结论
- sST2是HCT后最经充分验证的生物标志物,其从发现到临床相关的路径可为其他标志物提供参考。
研究设计与样本
- 综述,聚焦HCT后生物标志物从发现到首次临床相关的研究路径。
主要发现
- 血液生物标志物已在诊断测试、预测GVHD未来发生的预后测试以及预测GVHD治疗反应和非复发死亡的预测测试中获得验证。
- 基因组学、转录组学、蛋白质组学和细胞学技术的进步促进了上述标志物的发现与验证。
临床怎么用
- 血液生物标志物可能促进及时且选择性的治疗干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunotherapies have emerged as highly promising approaches to treat cancer patients. Allogeneic haematopoietic cell transplantation (HCT) is the most validated tumour immunotherapy available to date but its clinical efficacy is limited by toxicities, such as graft-versus-host disease (GVHD) and treatment resistance leading to relapse. The problems with new cellular therapies and checkpoint inhibitors are similar. However, development of biomarkers post-HCT, particularly for toxicities, has taken off in the last decade and has expanded greatly. Thanks to the advances in genomics, transcriptomics, proteomics and cytomics technologies, blood biomarkers have been identified and validated in promising diagnostic tests, prognostic tests stratifying for future occurrence of GVHD, and predictive tests for responsiveness to GVHD therapy and non-relapse mortality. These biomarkers may facilitate timely and selective therapeutic intervention. This review outlines a path from biomarker discovery to first clinical correlation, focusing on soluble STimulation-2 (sST2) - the interleukin (IL)-33-decoy receptor - which is the most validated biomarker.
引用
- Paczesny S. Post-haematopoietic cell transplantation outcomes: why ST2 became a 'golden nugget' biomarker. Br J Haematol. 2020. PMID: 32039480. doi:10.1111/bjh.16497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。